AVX 470

Drug Profile

AVX 470

Alternative Names: Avaximab-TNF; AVX-1350; AVX-470; AVX-470h

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Avaxia Biologics
  • Class Polyclonal antibodies
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Ulcerative colitis
  • Research Acute radiation syndrome

Most Recent Events

  • 07 Sep 2017 AVX 470 is available for licensing as of 07 Sep 2017. http://www.avaxiabiologics.com/partners/partners.php (Avaxia Biologics pipeline, September 2017)
  • 21 Jan 2015 Avaxia Biologics and Delphi Genetics enter into a manufacturing agreement for AVX 470
  • 21 Nov 2014 AVX 470 receives Orphan Drug status for Ulcerative colitis (In children, In infants, In adolescents) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top